Humoral immune response of a heterologous vaccination between BBIBP-CorV and BNT162b2 with a temporal separation of 7 months, in Peruvian health workers, with and without a history of SARS-CoV-2 infection
Published: 26 January 2022| Version 1 | DOI: 10.17632/ztps23g4sv.1
Contributor:
Jose Alonso Caceres Del AguilaDescription
This database corresponds to the humoral immunological results from health workers (in a private clinical laboratory) in Peru, who received the first two doses of BBIBP-CorV and seven months later a heterologous booster with BNT162b2. We employed two immunochemical assays to obtain the amount of neutralizing antibodies: Elecys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody assays to evaluate anti-S-RBD IgG and NAbs, respectively.
Files
Categories
Immunology, Vaccine, Neutralizing Antibody, Peru, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19